New cancer research foundation will help accelerate discoveries in glioblastoma, ovarian, and pancreatic cancers using a bold new approach.

CAMBRIDGE, Mass., April 19, 2022 – Today, one year after its founding, Break Through Cancer announced $50 million in grants to support several cutting-edge research projects using a novel “TeamLab” structure—designed to maximize interdisciplinary collaboration among researchers at Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, Koch Institute for Integrative Cancer Research at MIT, and The University of Texas MD Anderson Cancer Center. This first-of-its-kind model for collaboration enables researchers to boldly tackle some of the biggest challenges in cancer. Break Through Cancer hopes to overcome conventional barriers to multi-institution teamwork using streamlined systems and advanced analytics for data sharing in real time; umbrella contractual agreements that reduce administrative burdens on researchers; and pioneering policies on intellectual property and authorship.

The Foundation is funding four TeamLab-based research projects with an initial investment of more than $50 million in grants to bring new approaches and innovative ideas as rapidly as possible to the clinical challenges of glioblastoma, ovarian, and pancreatic cancers—diseases with poor prognoses in which progress has been slow.

“Break Through Cancer and its partner institutions are reducing the siloes in the academic research system as never before,” said Tyler Jacks, president, Break Through Cancer. “In just one year’s time, we have built an expansive and impressive community of leading cancer researchers and physicians who can now work as one to accelerate the pace of discovery. This model of radical collaboration will empower many of the brightest minds in cancer research and maximize the capabilities of partner institutions.”

Added Jacks, “In the near future, we look forward to partnering with pharmaceutical and biotechnology companies as well as technology developers to further expand the impact of Break Through Cancer.”

“To be part of Break Through Cancer’s new model of research collaboration is extremely exciting,” said Rebecca Stone, MD, MS, director of the Kelly Gynecologic Oncology Service, associate professor of Gynecology and Obstetrics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and a principal investigator for Break Through Cancer’s funded research in ovarian cancer. “Break Through Cancer has created a fertile ecosystem for nurturing new ideas and rapidly bringing laboratory discovery to advance cancer care. We are confident this initiative will accelerate progress in a meaningful way. So many lives are counting on it.”

Break Through Cancer’s initial investment of $50 million will fund the following research projects for an initial three-year period and will include researchers and physicians from all five partner institutions.

Intercepting Ovarian Cancer

  • Recent research has shown that most, if not all, high grade serous ovarian cancer originates as precursor lesions of the fallopian tubes. This presents an opportunity to reduce ovarian cancer incidence by exploring the impact of fallopian tube removal as a primary prevention strategy (known as opportunistic or prophylactic salpingectomy).
  • The team will develop strategies to expand awareness of and access to safe and effective ways for women to undergo opportunistic salpingectomy, particularly in women who are done having children and are already undergoing elective abdominal surgeries.
  • The team will create a new cross-specialty collaboration between gynecologic and general surgeons, advocate for universal health insurance coverage for opportunistic salpingectomy and create a national registry of women who elect this preventative intervention.
  • The culmination of the project will be a public health campaign to educate women about opportunistic salpingectomy and empower them to decrease their risk of ovarian cancer.
  • At the same time, the Intercepting Ovarian Cancer team will create an ovarian “pre-cancer atlas” by conducting exhaustive molecular analyses on many rare, pre-cancerous fallopian tube lesions obtained from all four participating cancer centers.
  • The team will identify new biomarkers that can be used to advance ovarian cancer screening and new, cutting-edge technologies for detecting and analyzing pre-cancers, including “OvaSeek,” a system that will rapidly image excised fallopian tubes and the “iCollector” to nondestructively harvest living cells from fallopian tube lesions.

Targeting Minimal Residual Disease in Ovarian Cancer

  • The majority of patients with ovarian cancer are diagnosed with late-stage disease. These women face cure rates as low as 15% depending on the subtype of ovarian cancer, a statistic that has not changed over the past several decades.
  • A key factor underlying these poor cure rates is the ability of cancer cells resistant to chemotherapy to persist after frontline treatment.
  • This persistent minimal residual disease (MRD) is clinically undetectable and represents “the seed” that eventually manifests as cancer recurrence.
  • The goal of this project is to transform the care of women with ovarian cancer by developing unprecedented capabilities for understanding and targeting MRD.
  • To do this, the team will develop and benchmark the accuracy of new blood biopsy and “second-look” surgical technologies to monitor this state at high resolution including extensive use of single-cell analysis.
  • Currently, trials of investigational frontline therapies use progression-free survival as their primary endpoint. Significant costs and long duration of these trials stifle innovation and development of more effective initial therapies. This project includes a clinical trial to use the rate of MRD after frontline therapy as a primary endpoint, de-risking testing of novel frontline therapies.

Revolutionizing GBM Drug Development Through Serial Biopsies

  • Therapeutic development for glioblastoma (GBM) has been stunted following several large and expensive phase III clinical trials that failed, despite encouraging preliminary results.
  • A central challenge is the complexity of the human brain, which cannot be modeled perfectly in the laboratory.
  • The Revolutionizing GBM Drug Development Through Serial Biopsies project will demonstrate the safety and feasibility of carefully performed serial biopsies, while in parallel assess how promising new therapies directly affect these brain tumors. The team will investigate whether samples of cerebrospinal fluid and/or blood from patients may provide surrogate markers of drug activity.
  • The objective of the project is to establish a new paradigm of therapy development for GBM by utilizing longitudinal biopsies in the same patient to determine which therapies are successfully delivered to the tumor and exert an intended effect—two major hurdles which have historically hindered therapeutic advances.
  • The extraordinary level of funding support from Break Through Cancer, highly unusual in GBM research, will be essential to overcoming many financial and logistical barriers to converting the vision of longitudinal tumor sampling into a reality.

Conquering KRAS in Pancreatic Cancer in partnership with the Lustgarten Foundation

  • The KRAS gene, which is altered in more than 90% of pancreas cancers, has long been believed to be undruggable.
  • With many promising new KRAS-targeting therapies either now available or on the horizon, the field may be on the cusp of a revolution in treatment for patients with pancreatic cancer.
  • The Conquering KRAS in Pancreatic Cancer team will integrate clinical and laboratory approaches to understand why patients do or do not respond to the new therapies using breakthrough single-cell technologies to deeply investigate biology in organoids, mice, and humans.
  • The team will develop pharmaceutical partnerships to accelerate the translation of new KRAS inhibitors into effective drugs for this disease. The large number of patients at Break Through Cancer partner institutions will enable trials that would be difficult at a single institution since some patients have rare but important KRAS mutations.
  • The Conquering KRAS in Pancreatic Cancer project will be supported in partnership with the Lustgarten Foundation.

About Break Through Cancer

Founded in 2021, Break Through Cancer empowers outstanding researchers and physicians to both intercept and find cures for several of the deadliest cancers by stimulating radical collaboration among outstanding cancer research institutions, including Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT’s Koch Institute for Integrative Cancer Research, and University of Texas M.D. Anderson Cancer Center. Break Through Cancer is looking beyond conventional therapies, utilizing new strategies, structures, and thinking from across disciplines to accelerate the pace of discovery.

Break Through Cancer is led by Tyler Jacks, PhD, founding director of MIT’s Koch Institute for Integrative Cancer Research, the David H. Koch (1962) Professor of Biology, and Co-director of the Ludwig Center at MIT. The Foundation is supported by a board that includes leaders from each of the five Break Through Cancer partner institutions and by a Scientific Advisory Board made of cancer experts from around the country. The foundation was launched with an extraordinary challenge pledge of $250 million from Mr. and Mrs. William H. Goodwin, Jr. and their family, and the estate of William Hunter Goodwin III. However, this is a fraction of the funding and resources that are needed to solve the complex problems the cancer community faces. We will need the support and creative minds from across the public and private ecosystem to make this happen. We are just getting started. breakthroughcancer.org, LinkedIn, Twitter

 

#  #  #

 

 

 

 

 

 

 

 

News